Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Motohiro Kojima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6150-6545; OpenAlex author ID A5084852275, A5100997688. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 18

  1. Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/pharmaceutics17010009↗
  2. Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma. First author DOI 10.1111/cas.15853↗
  3. Concordance of the histological diagnosis of type 1 autoimmune pancreatitis and its distinction from pancreatic ductal adenocarcinoma with endoscopic ultrasoun… Co-author DOI 10.1007/s00428-021-03236-w↗
  4. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  5. Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy. Last author DOI 10.3892/or.2022.8332↗
  6. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.09.006↗
  7. Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Co-author DOI 10.1038/s41598-021-86152-y↗
  8. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  9. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Last author DOI 10.1111/cas.14914↗
  10. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
  11. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
  12. Clinical Utility of Histological and Radiological Evaluations of Tumor Necrosis for Predicting Prognosis in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001539↗
  13. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model. Co-author DOI 10.1186/s12876-020-01556-w↗
  14. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  15. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-019-53801-2↗
  16. Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001369↗
  17. Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. First author DOI 10.1097/mpa.0000000000001106↗
  18. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, pr… Co-author DOI 10.1136/bmjopen-2017-018445↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoto Gotohda · 8 shared papers, 2018–2023 · strength 0.96
  2. Shinichiro Takahashi · 9 shared papers, 2017–2022 · strength 0.94
  3. Katsuhiko Uesaka · 5 shared papers, 2017–2022 · strength 0.50
  4. Shin Kobayashi · 4 shared papers, 2018–2023 · strength 0.49
  5. Motokazu Sugimoto · 4 shared papers, 2018–2023 · strength 0.49
  6. Hirochika Toyama · 4 shared papers, 2019–2022 · strength 0.42
  7. Soichiro Morinaga · 4 shared papers, 2019–2022 · strength 0.42
  8. Kenichi Hirabayashi · 4 shared papers, 2020–2022 · strength 0.41
  9. Horacio Cabral · 3 shared papers, 2020–2023 · strength 0.41
  10. Masashi Kudo · 3 shared papers, 2020–2023 · strength 0.41
  11. Yoko Matsuda · 4 shared papers, 2019–2021 · strength 0.41
  12. Tetsuo Akimoto · 4 shared papers, 2017–2022 · strength 0.40
  13. Masafumi Ikeda · 4 shared papers, 2017–2022 · strength 0.39
  14. Atsushi Ochiai · 3 shared papers, 2019–2020 · strength 0.35
  15. Mari A. Mino-Kenudson · 3 shared papers, 2019–2021 · strength 0.29
  16. Yasunori Nishida · 2 shared papers, 2019–2020 · strength 0.25
  17. Keiko Yamakawa · 2 shared papers, 2021 · strength 0.22
  18. Juanjuan Ye · 2 shared papers, 2021 · strength 0.22
  19. Masanao Yokohira · 2 shared papers, 2021 · strength 0.22
  20. Yasuyuki Suzuki · 2 shared papers, 2021 · strength 0.22
  21. Keiichi Okano · 2 shared papers, 2021 · strength 0.22
  22. Norihisa Takakura · 2 shared papers, 2020–2022 · strength 0.21
  23. Keishi Sugimachi · 2 shared papers, 2020–2022 · strength 0.21
  24. Atsushi Miyamoto · 2 shared papers, 2020–2022 · strength 0.21
  25. Wataru Takayama · 2 shared papers, 2020–2022 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.